1. For patients with persistent asthma symptoms and/or exacerbations despite low-dose inhaled corticosteroids, stepping up pharmacotherapy can be considered. Which of the following is NOT recommended?

2. Which of the following asthma therapies is a human monoclonal IgG4 antibody that inhibits interleukin (IL)-4 and IL-13 signaling by binding to the IL-4Rα subunit?

3. Which of the following is NOT a contributing factor to a successful patient-reported outcomes program in asthma therapy management?

4. According to the 2020 Global Initiative for Asthma (GINA 2020) guidelines, which of the following monitoring parameters best assesses a patient's asthma management?

5. CC is a 25-year-old female who presents to the clinic for a follow-up asthma appointment. Her past medical history is significant for moderate persistent asthma, gastroesophageal reflux disease, and seasonal allergic rhinitis. CC is a current smoker, smoking approximately 1 pack of cigarettes per day. Her current medication regimen includes fluticasone/salmeterol 250/50 mcg dry powder inhaler, 1 inhalation twice daily; albuterol 90 mcg HFA, 2 inhalations every 4 to 6 hours as needed; omeprazole 20 mg orally daily; and cetirizine 10 mg orally daily. CC has no known drug allergies. She reports having had asthma symptoms that required the use of her rescue inhaler at least 4 times per week over the last month. After further inquiry, the patient admits to regularly forgetting the evening dose (approximately 50% of the prescribed doses) of her maintenance inhaler (fluticasone/salmeterol 250/50 mcg). Spirometry results are measured and the patient's forced expiratory volume in 1 second (FEV1) is 67% predicted. For CC, what action would not play a role in improving patient-reported outcomes?

Evaluation Questions

6. How confident are in your role in using patient-reported outcomes to guide treatment planning?

« Return to Activity